BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pan S, Deng Y, Fu J, Zhang Y, Zhang Z, Qin X. N6‑methyladenosine upregulates miR‑181d‑5p in exosomes derived from cancer‑associated fibroblasts to inhibit 5‑FU sensitivity by targeting NCALD in colorectal cancer. Int J Oncol 2022;60:14. [PMID: 35014676 DOI: 10.3892/ijo.2022.5304] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Ponzetti M, Rucci N, Falone S. RNA methylation and cellular response to oxidative stress-promoting anticancer agents. Cell Cycle 2023;:1-36. [PMID: 36648057 DOI: 10.1080/15384101.2023.2165632] [Reference Citation Analysis]
2 Pliakou E, Lampropoulou DI, Dovrolis N, Chrysikos D, Filippou D, Papadimitriou C, Vezakis A, Aravantinos G, Gazouli M. Circulating miRNA Expression Profiles and Machine Learning Models in Association with Response to Irinotecan-Based Treatment in Metastatic Colorectal Cancer. Int J Mol Sci 2022;24. [PMID: 36613487 DOI: 10.3390/ijms24010046] [Reference Citation Analysis]
3 Zaoqu Liu, Haijiao Zou, Qin Dang, Hui Xu, Long Liu, Yuyuan Zhang, Jinxiang Lv, Huanyun Li, Zhaokai Zhou, Xinwei Han. Biological and pharmacological roles of m6A modifications in cancer drug resistance. Mol Cancer 2022;21:220. [PMID: 36517820 DOI: 10.1186/s12943-022-01680-z] [Reference Citation Analysis]
4 Villanueva JW, Kwong L, Han T, Martinez SA, Shanahan MT, Kanke M, Dow LE, Danko CG, Sethupathy P. Comprehensive microRNA analysis across genome-edited colorectal cancer organoid models reveals miR-24 as a candidate regulator of cell survival. BMC Genomics 2022;23:792. [DOI: 10.1186/s12864-022-09018-1] [Reference Citation Analysis]
5 Ma M, Ye T, Wang J, Zhao H, Zhang S, Li P, Zhao G. N6-methyladenosine Modification of Noncoding RNAs: Mechanisms and Clinical Applications in Cancer. Diagnostics (Basel) 2022;12. [PMID: 36553003 DOI: 10.3390/diagnostics12122996] [Reference Citation Analysis]
6 Naito Y, Yoshioka Y, Ochiya T. Intercellular crosstalk between cancer cells and cancer-associated fibroblasts via extracellular vesicles. Cancer Cell Int 2022;22:367. [PMID: 36424598 DOI: 10.1186/s12935-022-02784-8] [Reference Citation Analysis]
7 Su Z, Xu L, Dai X, Zhu M, Chen X, Li Y, Li J, Ge R, Cheng B, Wang Y. Prognostic and clinicopathological value of m6A regulators in human cancers: a meta-analysis. Aging 2022. [DOI: 10.18632/aging.204371] [Reference Citation Analysis]
8 Yang Z, Zhang S, Xia T, Fan Y, Shan Y, Zhang K, Xiong J, Gu M, You B. RNA Modifications Meet Tumors. CMAR 2022;Volume 14:3223-3243. [DOI: 10.2147/cmar.s391067] [Reference Citation Analysis]
9 Li Y, Li X, Deng M, Ye C, Peng Y, Lu Y, Liang S. Cancer-Associated Fibroblasts Hinder Lung Squamous Cell Carcinoma Oxidative Stress-Induced Apoptosis via METTL3 Mediated m6A Methylation of COL10A1. Oxidative Medicine and Cellular Longevity 2022;2022:1-13. [DOI: 10.1155/2022/4320809] [Reference Citation Analysis]
10 Yuan H, Chen B, Chai R, Gong W, Wan Z, Zheng B, Hu X, Guo Y, Gao S, Dai Q, Yu P, Tu S. Loss of exosomal micro-RNA-200b-3p from hypoxia cancer-associated fibroblasts reduces sensitivity to 5-flourouracil in colorectal cancer through targeting high-mobility group box 3. Front Oncol 2022;12:920131. [DOI: 10.3389/fonc.2022.920131] [Reference Citation Analysis]
11 Konrad SM, Schwamborn K, Krüger A, Honert K, Schmitt M, Hellmann D, Schmalfeldt B, Meindl A, Kiechle M, Quante AS, Brambs C, Grill S, Ramser J. NCALD as a potential predictive biomarker for the efficacy of platinum-based chemotherapy in ovarian cancer. Biomark Med 2022;16:1029-41. [PMID: 36444691 DOI: 10.2217/bmm-2021-0781] [Reference Citation Analysis]
12 Wei S, Hu W, Feng J, Geng Y. Promotion or remission: a role of noncoding RNAs in colorectal cancer resistance to anti-EGFR therapy. Cell Commun Signal 2022;20:150. [PMID: 36131281 DOI: 10.1186/s12964-022-00960-x] [Reference Citation Analysis]
13 Zhang F, Liu H, Duan M, Wang G, Zhang Z, Wang Y, Qian Y, Yang Z, Jiang X. Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application. J Hematol Oncol 2022;15. [DOI: 10.1186/s13045-022-01304-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
14 Xia Z, Kong F, Wang K, Zhang X. Role of N6-Methyladenosine Methylation Regulators in the Drug Therapy of Digestive System Tumours. Front Pharmacol 2022;13:908079. [PMID: 35754499 DOI: 10.3389/fphar.2022.908079] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Chen X, Jia M, Ji J, Zhao Z, Zhao Y. Exosome-Derived Non-Coding RNAs in the Tumor Microenvironment of Colorectal Cancer: Possible Functions, Mechanisms and Clinical Applications. Front Oncol 2022;12:887532. [PMID: 35646623 DOI: 10.3389/fonc.2022.887532] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Villanueva JW, Kwong L, Han T, Martinez SA, Shanahan MT, Kanke M, Dow LE, Danko CG, Sethupathy P. Genome edited colorectal cancer organoid models reveal distinct microRNA activity patterns across different mutation profiles.. [DOI: 10.1101/2021.12.13.472432] [Reference Citation Analysis]